CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

CDMO Subsection

Insights into the latest developments in CDMO services and manufacturing.

Continue reading

Injectables Subsection

Expert perspectives on the evolving needs of injectable therapies and packaging.

Continue reading

Nasal & Pulmonary Subsection

Exploring the latest developments in inhalation technologies, respiratory delivery and sustainability

Continue reading

Advertisement

CPHI Milan
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Lifecore Biomedical

Advertisement

Solstice
Revisited Cell Cultures and Valuable Methods for Pre-clinical Studies
Clinical Research V6I4

Revisited Cell Cultures and Valuable Methods for Pre-clinical Studies

During the last ten years, the development of transgenic techniques has rendered possible the creation of mutant strains of rodents mimicking human diseases and the ...
Continue Reading →
Special Report – How to Ensure the Proper Behaviour of Excipients and their Best Possible Use
Drug Discovery, Development & Delivery V6I4

Special Report – How to Ensure the Proper Behaviour of Excipients and their Best Possible Use

As in recent years excipients have proved to be anything but “inert”, ensuring the proper behaviour of excipients in the various phases of the industrial production ...
Continue Reading →
The Expanding Role of MRI in the Pharmaceutical Industry
Drug Discovery, Development & Delivery V6I4

The Expanding Role of MRI in the Pharmaceutical Industry

With ever-increasing pressure on drug development pipelines and a growing need to demonstrate convincing mechanisms of action as a part of the registration process f...
Continue Reading →
Developing Healthcare Facilities
Regulatory & Marketplace V6I4

Developing Healthcare Facilities

If you are the operator of a nursing or care home, and you are considering commissioning the building of a new care or nursing home, or extending or refurbishing an ...
Continue Reading →
ISO IDMP – Four Challenges in Preparing Organisations for the July 1, 2016 EMA Deadline
Regulatory & Marketplace V6I4

ISO IDMP – Four Challenges in Preparing Organisations for the July 1, 2016 EMA Deadline

Most pharmaceutical companies face challenges in becoming compliant with the ISO IDMP standards. In this article, Rune Bergendorff, responsible for NNIT’s ISO IDMP s...
Continue Reading →
Regulatory & Marketplace V6I4

How Much Data Should You Include in a Patent Application?

In the life sciences and chemistry fields it is important to be aware that a perceived lack of data in a patent application can have an impact on the eventual scope ...
Continue Reading →
A Hard Pill to Swallow: Meeting the Needs of Modern Consumers
Regulatory & Marketplace V6I4

A Hard Pill to Swallow: Meeting the Needs of Modern Consumers

Confronted with the “patent cliff”, dwindling drug discovery success and a host of other challenges, pharmaceutical companies are being forced to reconsider how they...
Continue Reading →
Cost Savings for Healthcare Estates: Delivered through Improved Waste Management
Regulatory & Marketplace V6I4

Cost Savings for Healthcare Estates: Delivered through Improved Waste Management

You only have to read a newspaper or turn on the news to see how the NHS is struggling to meet the balance between demand for healthcare services and funding. Tony M...
Continue Reading →
“Personal Pill” Regulations: Current Landscape and Future Scenario
Regulatory & Marketplace V6I4

“Personal Pill” Regulations: Current Landscape and Future Scenario

The rapidly-evolving science of pharmacogenetics brought in the amazing concept of “personalisation of medicines” also referred to as the “personal pill”. Balamurali...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Tjoapack
Aptar – 08/01/2026